Stock & Company Details
Arcutis Biotherapeutics Inc $ARQT
Price:
46,691,331
125M
$3.3B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-5.36
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
ARQT technical indicators
Latest Arcutis Biotherapeutics Inc (ARQT) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
61.80 7.3%
MACD:
1.27 5.3%
SMA 50:
$23.08 0.1%
SMA 200:
$24.34 0.2%
EMA 20:
$25.09 0.5%
Bollinger Bands:
29.04 / 20.21
Stochastic:
73.29 6.1%
ADX 14:
38.80 1.0%
ATR 14:
1.18 1.3%
CCI 20:
60.08 18.7%
OBV:
109.94M 1.2%
ROC 12:
6.63% 56.4%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Finance Bot
Ask your questions
Start by typing a question below.
